Jacalyn Lee, founder of The DAND Alliance, is partnering with the startup Nome to develop treatments for her daughter's rare genetic disorder. Nome uses AI to provide research roadmaps and project management for families facing ultra-rare conditions.
Joshua Pederson, father of a 12-year-old cancer survivor, condemns prediction markets like Kalshi and Polymarket for allowing bets on clinical trial outcomes, arguing it creates unethical incentives and distances bettors from the human cost.
The US faces its highest measles cases in decades amid declining vaccination rates, prompting researchers to develop treatments for those infected or vulnerable.
AstraZeneca CEO Pascal Soriot discusses how AI enhances productivity in drug discovery and development, enabling smarter design, side effect reduction, and improved trial success prediction.
Celltrion announced on the 26th its plan to strengthen competitiveness by introducing AI in new drug development and manufacturing. The company aims to significantly shorten the drug development period, which typically takes over 10 years, by utilizing AI for candidate substance discovery and verification.
METiS TechBio, an AI-driven drug design start-up, made a strong debut on the Hong Kong stock market, raising HK$2.11 billion. CEO Lai Tsai-Ta compared the company to SpaceX, highlighting its use of AI algorithms for rapid drug development through nano-delivery platforms.
Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion. Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan. The deal adds credibility to China’s growing reputation for innovative drug development. Industry players, however, said the country...
GSK has announced promising early-stage trial results for its cancer treatment Mo-Rez, which showed high efficacy in shrinking tumors for ovarian and endometrial cancer patients. The company plans to move directly to late-stage clinical trials.
